CureDuchenne Blog

Sarepta to File Eteplirsen NDA by Year End

Summary from Seeking Alpha Based on updated guidance from the FDA regarding an  early approval pathway for eteplirsen, Sarepta Therapeutics (SRPT) plans to file an NDA by the end of 2014. The […]

Drisapersen Update with Prosensa

Prosensa will present a status update on Drisapersen and its follow-on compounds in a patient focused webinar hosted by United Parent Projects Muscular Dystrophy (UPPMD) on Tuesday, March 25 at […]

Prosensa Patient Webinar

Dr. Giles Campion, Prosensa’s Chief Medical Officer ( presented an overview of the latest drisapersen results in this morning’s patient webinar. An analysis of the Phase III data suggests that […]